A phase II clinical trial in China evaluating the effectiveness of imatinib in 43 metastatic melanoma patients (AM = 21) harboring c-Kit mutation or amplification showed a median PFS of 3.5 months, a 6-month PFS rate of 36.6%, and DCR of 53.5% [59]. Here, KIT is linked to metastatic melanoma.